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A massive gross haematuria in an 
85-year-old patient with acquired
haemophilia A
AbstrAct:
The authors herein present a case report of an 85-year-old female patient with massive gross haematuria in the 
course of acquired haemophilia A. Acquired haemophilia in the geriatric population is a rare but severe 
bleeding disorder. It is caused by suddenly appearing autoantibodies that interfere with coagulation factor 
VIII activity. The diagnosis of acquired haemophilia should be considered in any patient who presents with 
bleeding and a prolonged activated partial thromboplastin time (APTT).
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Introduction:
Haemophilia is the oldest known hereditary bleeding 
disorder, recognised even in ancient times. There are 
three types of the disease: haemophilia A, haemophilia 
B, and haemophilia C. Haemophilia A is caused by a de-
crease in plasma coagulation factor VIII activity, haemo-
philia B by a decrease in plasma coagulation factor IX, 
and haemophilia C by a decrease in plasma coagulation 
factor XI. Depending on the degree of deficiency of 
the coagulation factor, the following are distinguished: 
severe (< 1% of norm), moderate (1–5% of norm), and 
mild (5–50% of norm). Almost half of the recognised 
forms of haemophilia are classified as severe. The 
most typical symptom of haemophilia is spontaneous 
haemarthrosis, which leads to joint destruction (hae-
mophilic arthropathy) and secondary muscle atrophies. 
In addition, intra-muscular bleeding, haematuria, gas-
trointestinal bleeding, intracranial bleeding (a frequent 
cause of death), and bleeding from surgical and dental 
extraction wounds may occur primarily in the severe 
form of the disease. At present, there is no causative 
treatment of the disease available and no full recovery 
is possible. Supplementation with concentrates of de-
ficient coagulation factors is used. The implementation 
of such treatment results in a significant extension and 
improvement in the quality of the patients’ lives [1–2]. 
Although haemophilia is usually associated with a ge-
netically conditioned disorder, it also occurs throughout 
life as an acquired haemophilia. The disease in this form 
especially affects elderly patients.
Case report:
An eighty-five-year-old female patient was admitted 
to the Geriatric Clinic due to massive gross haematuria 
observed by the patient and the patient’s relatives five 
days before she appeared in the Hospital Emergency 
Department. The symptoms were accompanied by 
diffuse lower abdominal pain and increased body 
temperature (the highest observed fever was 39°C).
In the patient’s history, persistent atrial fibrillation, 
moderate mitral regurgitation, and chronic obstructive 
pulmonary disease and nicotinism were reported. The 
patient had taken chronically (for three years) dabig-
atran at a reduced dose due to old age (2x110 mg), 
metoprolol in extended-release form (1x25 mg), 
spironolactone (1x25 mg), sustained-release form of 
indapamide (1x1.5 mg), simvastatin (1x20 mg), and 
inhalants: formoterol 12 µg (2x1) and budesonide 
400 µg (2x1).
At admission, the patient was conscious, her general 
condition was described as mean, blood pressure (RR) 
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Table 1. Patient’s laboratory findings.
Test name Patient’s test results Normal limits
WBC 10.48 10^3/ul 3.98-10.04 10^3/ul
RBC 4.65 10^6/ul 3.93-5.22 10^6/ul
HGB 13.4 g/dl 11.2-15.7 g/dl
MCV 88.4 fl 79.4-94.8 fl
PLT 191 10^3/ul 132-370 10^3/ul
CRP 19.58 mg/l <5.00 mg/l
Creatinine 0.85 mg/dl 0.6-1.10 mg/dl
Potassium 3.7 mmol/l 3.5-5.0 mmol/l
Sodium 138.2 mmol/l 136-145 mmol/l
ALT 10 U/l <36 U/l
AST 17 U/l <34 U/l
Amylase in body fluids 124 U/l 5-410 U/l
Total bilirubin 0.78 mg/dl 0.2-1.2 mg/dl
APTT 157.2 s 26.4-37.5 s
INR 1.24 0.9-1.2
PT 15.6 9.4-13.8
100/60, atrial fibrillation with mean ventricular function 
about 80/min, 16 breaths/min, physiological vesicular 
murmur, she walked by herself, but with difficulty, and 
she was without visible peripheral oedema and cutane-
ous lesions. In the physical examination, she empha-
sised tenderness of the abdomen, without features of 
muscle defence and peritoneal symptoms. Additional 
tests were carried out (see Table 1)
An issue requiring special attention was a  con-
siderably prolonged activated partial thromboplastin 
time (APTT). In the general urine test there were fields 
densely covered with erythrocytes, quite numerous 
bacteria, 10-20 leukocytes per high-power field, and 
a significant protein content of 267 mg/dl.
No abnormalities in the gall bladder and liver were 
found in the ultrasound performed in the abdominal 
cavity. In the body of the pancreas a hypoechoic area of 
13 × 6 × 9 mm was described for further diagnosis. On 
both sides, pelvicalyceal systems were marked, on the 
right side the calyx up to 8 mm wide and the renal pelvis 
6 mm wide, whereas on the left side the calyx up to 
10 mm wide and the renal pelvis 9 mm wide. Due to the 
urgency of the ultrasound examination, bladder filling 
was not achieved, and consequently no full assessment 
was possible. There was no evidence of free fluid in the 
abdominal cavity.
Based on the entire clinical presentation, suspicion 
of pyelonephritis was put forward, empiric antibiotic 
therapy with ceftriaxone (1 × 2 g) was administrated 
until the urinal culture examination results were ob-
tained. Due to the observed haematuria, dabigatran was 
discontinued (CHA2-DS2-Vasc 4 pkt HAS-BLED 3 pkt).
The patient was consulted urologically, and cys-
toscopy was performed in accordance with the recom-
mendations, which showed no pathological changes 
in the bladder, while the right ureter showed rhythmic 
projections of bloody urine. After the cystoscopic ex-
amination, the patient’s diagnosis was extended with 
a computed tomography of the abdominal cavity and 
pelvis revealing in the right renal pelvis a lack of contrast 
in the form of numerous thrombi. On the borderline 
of the head and body of the pancreas, the change 
previously described in the ultrasound examination, 
measuring 15 × 8 mm, hypodense, subject to slight 
contrast enhancement, was visualised.
During the hospitalisation, the patient was observed 
with a persistent gross haematuria, without significant 
improvement after the implemented conservative treat-
ment, and gradual anaemia of the patient (decrease in 
Hgb value to 8.8 g/dl), as well as massive ecchymosis 
at the injection sites. A decision was made to extend the 
diagnosis of coagulation disorders - a correction test 
and determination of coagulation factors were made 
(for results see Table 2).
The patient was consulted haematologically: on 
the basis of the recommendations issued, a  total of 
20,000 units of FEIBA (coagulation factor VIII inhibitor) 
was ordered from the Regional Blood Donation Centre 
and transfused, and prednisone 80 mg was added to 
the medication. After stabilisation of the patient’s con-
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Table 2. Correction test and determination of coagulation factor results.
Test name Patient’s test results Normal limits
Correction test No correction - after addition of normal serum, the APTT time was not normalised correction (+)
Factor VIII 0.5% 70-150%
Factor IX 88.90% 70-120%
Factor XI 53.60% 70-120%
dition, the patient was transferred to the Department of 
Haemostasis and Internal Disorders at the Institute of 
Haematology and Transfusion Medicine in Warsaw for 
further treatment.
Discussion:
The present case of an elderly patient with massive 
gross haematuria describes a  rare geriatric point of 
view. The primary cause of haematuria may be the use 
of the DOAC (direct oral anticoagulant) dabigatran. 
According to the Summary of Product Characteristics, 
patients aged 80 years and over should take a dose of 
220 mg in the form of one 110-mg capsule twice a day 
due to the increased risk of bleeding in this population 
[3]. The patient was treated according to the above 
recommendations. Dabigatran induces a  dose-de-
pendent and short-term (1-4 h after administration) 
prolongation of activated partial thromboplastin time 
(APTT) and prothrombin time (PT), while its effect on 
international normalised ratio (INR) is less reliable [4]. 
Prolongation of APTT four times and persistence of 
these values, despite the withdrawal from treatment 
with DOAC, excludes dabigatran as the cause of the 
observed disorders. The degree of haematuria is also 
not justified by the suspicion of urinary tract infection 
that has been raised during the diagnosis.
Isolated haematuria as a  symptom of acquired 
haemophilia is a  rarely observed phenomenon. Ac-
quired haemophilia is usually associated with multiple 
haemorrhagic complications, such as ecchymosis and 
haematomas within the skin and subcutaneous tissue 
(94%) or intra-articular bleeding (9%). There is also 
prolonged bleeding in places of intravenous injection 
and other iatrogenic interventions with disruption of 
tissues, bleeding into the gastrointestinal tract and 
central nervous system [5]. Mortality connected directly 
or indirectly with haemorrhagic complications reaches 
10–22% in the population of ill persons [7].
Acquired haemophilia A is a disease caused by the 
presence of autoantibodies that inhibit coagulation factor 
VIII activity. The occurrence of autoantibodies is a rare 
disorder detected in one person per 1-4 million of the 
general population. Acquired autoantibodies against 
coagulation factor VIII are polyclonal in nature and belong 
to the immunoglobulin IgG class [6]. The disease most 
often appears in older people aged 60-80 years. About 
50% of patients are diagnosed with the idiopathic form 
of the disease; in the remaining 50% at the time of di-
agnosis, a coexisting condition is detected, most often 
cancer (12.5%), rheumatoid arthritis (14.6%), systemic 
lupus (10.4%), or other autoimmune disorders (8.3%) [7].
Conclusions:
The patient’s case indicates the need to search for 
the causes of isolated haematuria in the elderly popu-
lation, also among rare in clinical practice conditions, 
including acquired coagulation disorders. Proper diag-
nosis and start of causative therapy is associated with 
a better prognosis and helps avoid factors increasing 
the risk of massive multi-organ bleeding.
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